Page 10 - Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery

The new engl and jour nal of medicine

thromboembolism in patients undergoing non- Disclosure forms provided by the authors are available with
major orthopedic surgery with a period of immo- the full text of this article at NEJM.org.
A data sharing statement provided by the authors is available
bilization. There was no significant difference be- with the full text of this article at NEJM.org.
tween rivaroxaban and enoxaparin in the risk of We thank Alain Baleydier, Annaëlle David, and Julie Bisiaux
major bleeding events. (of PSNResearch) for contributions to the trial and Sophie
Rushton-Smith (of MedLink Healthcare Communications) for
Supported by Centre Hospitalier Universitaire de Saint-Etienne medical writing assistance with an earlier version of the manu-
and Bayer. script under the direction of the authors.

Appendix
The authors’ affiliations are as follows: the Department of Anesthesia and Critical Care, Groupe Hospitalo-Universitaire Assistance
Publique–Hôpitaux de Paris Centre−Université de Paris, Hôpital Cochin (C.M.S., N.R.), Unité de Recherche Clinique, Innovation, Phar-
macologie, Centre Hospitalier Universitaire de Saint-Etienne, Sainboise INSERM Unité 1059, Université Jean Monnet, and INSERM
CIE1408 (S.L., B.D., E.P., P. Mismetti), French Clinical Research Infrastructure Network (F-CRIN), Investigation Network on Venous
Thromboembolism (INNOVTE) (S.L., P.G., P. Mismetti), and Institut du Thorax Curie-Montsouris, Institut Mutualiste Montsouris
(P.G.), Paris, INSERM Centre National de la Recherche Scientifique 5558, Université Claude Bernard, Université de Lyon, Lyon (M.C.),
and the Department of Anesthesia and Critical Care, Polyclinique du Parc, Saint Saulve (D.D.) — all in France; the Department of An-
esthesia and Critical Care, University Hospital Doctor Peset, Valencia (J.L.), and the Department of Anesthesia and Critical Care, Hos-
pital Universitario Fundación de Alcorcón, Madrid (J.M.-M.) — both in Spain; Sektionsleiter Endoprothetik, Sana Klinikum Offenbach,
Offenbach am Main, Germany (P. Mouret); and McGill University, Montreal (W.F.).

References
1. Colman RW, Marder VJ, Clowes AW, patients admitted to hospital: summary - nformation/ xarelto - epar - product
i
George JN, Goldhaber SZ, eds. Hemosta- of the NICE guideline. Heart 2009; 96: - nformation_en pdf).
.
i
sis and thrombosis: basic principles and 879-82. 11. European Medicines Agency. Guide-
clinical practice. 5th ed. Philadelphia: 6. Kearon C, Akl EA, Ornelas J, et al. An- line on clinical investigation of medicinal

Lippincott Williams & Wilkins, 2005. tithrombotic therapy for VTE disease: products for prevention of venous throm-
2. Falck-Ytter Y, Francis CW, Johanson CHEST guideline and expert panel report. boembolism (VTE) in patients undergo-
NA, et al. Prevention of VTE in orthopedic Chest 2016; 149: 315-52. ing high VTE-risk surgery. May 30, 2013
surgery patients: Antithrombotic Therapy 7. National Institute for Health and Care (https://www ema europa eu/ en/
.
.
.
and Prevention of Thrombosis, 9th ed: Excellence. Venous thromboembolism in documents/ scientific - guideline/ guideline
American College of Chest Physicians ev- over 16s: reducing the risk of hospital-ac- - clinical - investigation - medicinal
idence-based clinical practice guidelines. quired deep vein thrombosis or pulmo- - products - prevention - venous
Chest 2012; 141(2): Suppl: e278S-e325S. nary embolism. March 2018 (https://www - hromboembolism - vte - patients_en pdf).
.
t
3. Chapelle C, Rosencher N, Zufferey PJ, .nice org uk/ guidance/ ng89). 12. Bikdeli B, Visvanathan R, Jimenez D,
.
.
Mismetti P, Cucherat M, Laporte S. Pre- 8. Afshari A, Ageno W, Ahmed A, et al. Monreal M, Goldhaber SZ, Bikdeli B. Use
vention of venous thromboembolic events European guidelines on perioperative ve- of prophylaxis for prevention of venous
with low-molecular-weight heparin in the nous thromboembolism prophylaxis: ex- thromboembolism in patients with iso-
non-major orthopaedic setting: meta- ecutive summary. Eur J Anaesthesiol lated foot or ankle surgery: a systematic
analysis of randomized controlled trials. 2018; 35: 77-83. review and meta-analysis. Thromb Hae-
Arthroscopy 2014; 30: 987-96. 9. Turpie AGG, Lassen MR, Eriksson BI, most 2019; 19: 1686-94.
4. Samama C-M, Gafsou B, Jeandel T, et et al. Rivaroxaban for the prevention of 13. Robert-Ebadi H, Righini M. Manage-
al. Guidelines on perioperative venous venous thromboembolism after hip or knee ment of distal deep vein thrombosis.
thromboembolism prophylaxis: update arthroplasty: pooled analysis of four stud- Thromb Res 2017; 149: 48-55.
2011: short text. Ann Fr Anesth Reanim ies. Thromb Haemost 2011; 105: 444-53. 14. van Adrichem RA, Nemeth B, Algra A,
2011; 30: 947-51. (In French.) 10. European Medicines Agency. Sum- et al. Thromboprophylaxis after knee ar-
5. Hill J, Treasure T. Reducing the risk of mary of product characteristics: Xarelto throscopy and lower-leg casting. N Engl J
venous thromboembolism (deep vein (rivaroxaban). 2018 (https://www ema Med 2017; 376: 515-25.
.
.
thrombosis and pulmonary embolism) in europa eu/ en/ documents/ product Copyright © 2020 Massachusetts Medical Society.
.

10 n engl j med nejm.org

The New England Journal of Medicine
Downloaded from nejm.org by Obai Mahmoud on March 31, 2020. For personal use only. No other uses without permission.
Copyright © 2020 Massachusetts Medical Society. All rights reserved.